

In re of Appl. No. 09/441,140

(ii) said antibody and said fragment inhibit aggregation of beta-amyloid; and

(B) a pharmaceutically acceptable carrier.

151. The pharmaceutical formulation of claim 150, wherein said antibody is a monoclonal antibody.

152. The pharmaceutical formulation of claim 151, wherein said antibody is a human monoclonal antibody.

153. The pharmaceutical formulation of claim 151, wherein said antibody is a genetically-engineered monoclonal antibody.

154. The pharmaceutical formulation of claim 153, wherein said antibody is a single-chain antibody.

155. The pharmaceutical formulation of any one of claims 150-154, wherein said beta-amyloid is human beta-amyloid.

156. A pharmaceutical formulation, comprising:

(A) an antibody or antigen binding fragment thereof,
wherein:

(i) said antibody is obtainable using residues 1-28 of beta-amyloid as an immunogen, and

(ii) said antibody and said fragment inhibit aggregation of beta-amyloid; and

(B) a pharmaceutically acceptable carrier.

In re of Appln. No. 09/441,140

157. The pharmaceutical formulation of claim 156, wherein said antibody is a monoclonal antibody.

158. The pharmaceutical formulation of claim 157, wherein said antibody is a human monoclonal antibody.

159. The pharmaceutical formulation of claim 157, wherein said antibody is a genetically-engineered monoclonal antibody.

160. The pharmaceutical formulation of claim 159, wherein said antibody is a single-chain antibody.

161. The pharmaceutical formulation of any one of claims 156-160, wherein said beta-amyloid is human beta-amyloid.

162. A pharmaceutical formulation, comprising:
(A) an antibody or antigen binding fragment thereof,
wherein:

(i) said antibody and said fragment recognize an epitope within residues 1-28 of beta-amyloid, and

(ii) said antibody and said fragment maintain the solubility of soluble beta-amyloid; and

(B) a pharmaceutically acceptable carrier.

163. The pharmaceutical formulation of claim 162, wherein said antibody is a monoclonal antibody.

164. The pharmaceutical formulation of claim 163, wherein said antibody is a human monoclonal antibody.